Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02.Key Highlights:Original SEC Filing: Armata Pharmaceuticals, Inc. [ ARMP ] - 8-K - Sep. 23, 2026This is an AI-powered summary. It may contain inac…
Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium ("MTEC") and managed by the Naval Medical Research Command ("NMRC") — Naval Advanced Medical Development ("NA
ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development